The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation
Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010907200 · Cited by 1,096
Research works printed but not linked: 61
- Langston, 2006, The Parkinson's complex: parkinsonism is just the tip of the iceberg, Ann. Neurol, 59, 591, 10.1002/ana.20834 · DOI · Paper page
- Langston, 1983, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, 979, 10.1126/science.6823561 · DOI · Paper page
- Sulzer, 2007, Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease, Trends Neurosci, 30, 244, 10.1016/j.tins.2007.03.009 · DOI · Paper page
- Spillantini, 1997, α-Synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 · DOI · Paper page
- Spillantini, 1998, α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U.S.A, 95, 6469, 10.1073/pnas.95.11.6469 · DOI · Paper page
- Polymeropoulos, 1997, Mutation in the α-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045 · DOI · Paper page
- Xu, 2002, Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease, Nat. Med, 8, 600, 10.1038/nm0602-600 · DOI · Paper page
- Hasegawa, 2006, α-Synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease, FEBS Lett, 580, 2147, 10.1016/j.febslet.2006.03.018 · DOI
- Filloux, 1993, Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection, Exp. Neurol, 119, 79, 10.1006/exnr.1993.1008 · DOI · Paper page
- Follmer, 2014, Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy, Exp. Rev. Neurother, 14, 703, 10.1586/14737175.2014.920235 · DOI
- Burke, 2003, 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis, Brain Res, 989, 205, 10.1016/S0006-8993(03)03354-7 · DOI · Paper page
- Goldstein, 2011, Catechols in post-mortem brain of patients with Parkinson disease, Eur. J. Neurol, 18, 703, 10.1111/j.1468-1331.2010.03246.x · DOI
- Goldstein, 2013, Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease, J. Neurochem, 126, 591, 10.1111/jnc.12345 · DOI · Paper page
- Fitzmaurice, 2013, Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease, Proc. Natl. Acad. Sci. U.S.A, 110, 636, 10.1073/pnas.1220399110 · DOI · Paper page
- Burke, 2008, Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine, Acta Neuropathol, 115, 193, 10.1007/s00401-007-0303-9 · DOI · Paper page
- Coelho-Cerqueira, 2013, α-Synuclein as an intrinsically disordered monomer–fact or artefact?, FEBS J, 280, 4915, 10.1111/febs.12471 · DOI
- Anderson, 2011, Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone, J. Biol. Chem, 286, 26978, 10.1074/jbc.M111.249532 · DOI
- Abramoff, 2004, Image processing with ImageJ, Biophot. Int, 11, 36
- Delaglio, 1995, NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR, 6, 277, 10.1007/BF00197809 · DOI · Paper page
- Bermel, 2006, Protonless NMR experiments for sequence-specific assignment of backbone nuclei in unfolded proteins, J. Am. Chem. Soc, 128, 3918, 10.1021/ja0582206 · DOI · Paper page
- Chandra, 2003, A broken α-helix in folded α-synuclein, J. Biol. Chem, 278, 15313, 10.1074/jbc.M213128200 · DOI · Paper page
- Eliezer, 2001, Conformational properties of α-synuclein in its free and lipid-associated states, J. Mol. Biol, 307, 1061, 10.1006/jmbi.2001.4538 · DOI · Paper page
- Eliezer, 2012, Distance information for disordered proteins from NMR and ESR measurements using paramagnetic spin labels, Methods Mol. Biol, 895, 127, 10.1007/978-1-61779-927-3_10 · doi:10.1007/978-1-61779-927-3_10
- Shvadchak, 2011, Specificity and kinetics of α-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe, J. Biol. Chem, 286, 13023, 10.1074/jbc.M110.204776 · DOI
- Ysselstein, 2015, Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity, Neurobiol. Dis, 79, 150, 10.1016/j.nbd.2015.04.007 · DOI
- Scholtz, 1991, Parameters of helix-coil transition theory for alanine-based peptides of varying chain lengths in water, Biopolymers, 31, 1463, 10.1002/bip.360311304 · DOI · Paper page
- Shvadchak, 2011, The mode of α-synuclein binding to membranes depends on lipid composition and lipid to protein ratio, FEBS Lett, 585, 3513, 10.1016/j.febslet.2011.10.006 · DOI
- Guang, 2006, High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay, Acta Pharmacol. Sin, 27, 760, 10.1111/j.1745-7254.2006.00336.x · DOI
- Dixon, 1968, Reversible blocking of free amines with citraconic anhydride, Biochem. J, 109, 312, 10.1042/bj1090312 · doi:10.1042/bj1090312
- Follmer, 2007, Dopamine affects the stability, hydration and packing of protofibrils and fibrils of wild-type and variants of α-synuclein, Biochemistry, 46, 472, 10.1021/bi061871+ · DOI
- Coelho-Cerqueira, 2014, Pitfalls associated with the use of thioflavin-T to monitor anti-fibrillogenic activity, Bioorg. Med. Chem. Lett, 24, 3194, 10.1016/j.bmcl.2014.04.072 · DOI
- Yagi, 2005, Amyloid fibril formation of α-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases, J. Biol. Chem, 280, 38609, 10.1074/jbc.M508623200 · DOI
- Leong, 2009, Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation, Free Radic. Biol. Med, 46, 1328, 10.1016/j.freeradbiomed.2009.02.009 · DOI
- Zhou, 2010, Met residues oxidation stabilizes non-toxic oligomers of α-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions, Biochim. Biophys. Acta, 1802, 322, 10.1016/j.bbadis.2009.12.004 · DOI
- Carmo-Gonçalves, 2014, UV-induced selective oxidation of Met-5 to Met-sulfoxide leads to the formation of neurotoxic fibril-incompetent α-synuclein oligomers, Amyloid, 21, 163, 10.3109/13506129.2014.912208 · DOI
- Rauniyar, 2009, Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications, Proteomics, 9, 5188, 10.1002/pmic.200900116 · DOI
- Li, 2005, Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino group of α-synuclein. Implication for dopaminergic neurodegeneration, FEBS J, 272, 3661, 10.1111/j.1742-4658.2005.04792.x · DOI
- Lin, 2005, 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal, Chem. Res. Toxicol, 18, 1219, 10.1021/tx050080q · DOI · Paper page
- Sung, 2007, Residual structure, backbone dynamics, and interactions within the synuclein family, J. Mol. Biol, 372, 689, 10.1016/j.jmb.2007.07.008 · DOI
- Kjaergaard, 2011, Sequence correction of random coil chemical shifts: correlation between neighbor correction factors and changes in the Ramachandran distribution, J. Biomol. NMR, 50, 157, 10.1007/s10858-011-9508-2 · DOI · Paper page
- Kjaergaard, 2011, Random coil chemical shifts for intrinsically disordered proteins: effects of temperature and pH, J. Biomol. NMR, 49, 139, 10.1007/s10858-011-9472-x · DOI · Paper page
- Lotharius, 2002, Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein, Nat. Rev. Neurosci, 3, 932, 10.1038/nrn983 · DOI · Paper page
- Fowler, 1997, Age-related increases in brain MAO B in healthy human subjects, Neurobiol. Aging, 18, 431, 10.1016/S0197-4580(97)00037-7 · DOI · Paper page
- Lamensdorf, 2000, Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde, J. Neurosci. Res, 60, 552, 10.1002/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U · DOI
- Mizuno, 1989, Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease, Biochem. Biophys. Res. Commun, 163, 1450, 10.1016/0006-291X(89)91141-8 · DOI · Paper page
- Conway, 2001, Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522 · DOI · Paper page
- Bisaglia, 2010, Dopamine quinones interact with α-synuclein to form unstructured adducts, Biochem. Biophys. Res. Commun, 394, 424, 10.1016/j.bbrc.2010.03.044 · DOI
- Qin, 2007, Effect of 4-hydroxy-2-nonenal modification on α-synuclein aggregation, J. Biol. Chem, 282, 5862, 10.1074/jbc.M608126200 · DOI · Paper page
- Rees, 2009, Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and catechol, Chem. Res. Toxicol, 22, 1256, 10.1021/tx9000557 · DOI
- Umanah, 2009, Cross-linking of a DOPA-containing peptide ligand into its G protein-coupled receptor, Biochemistry, 48, 2033, 10.1021/bi802061z · doi:10.1021/bi802061z
- Yu, 1999, Role of l-3, 4-dihydroxyphenylalanine in mussel adhesive proteins, J. Am. Chem. Soc, 121, 5825, 10.1021/ja990469y · DOI · Paper page
- Georgieva, 2008, Membrane-bound α-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles, J. Am. Chem. Soc, 130, 12856, 10.1021/ja804517m · DOI · Paper page
- Bussell, 2003, structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins, J. Mol. Biol, 329, 763, 10.1016/S0022-2836(03)00520-5 · DOI · Paper page
- Ulmer, 2005, Structure and dynamics of micelle-bound human α-synuclein, J. Biol. Chem, 280, 9595, 10.1074/jbc.M411805200 · DOI · Paper page
- Snead, 2014, α-Synuclein function and dysfunction on cellular membranes, Exp. Neurobiol, 23, 292, 10.5607/en.2014.23.4.292 · DOI · Paper page
- Burré, 2012, Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities, J. Neurosci, 32, 15227, 10.1523/JNEUROSCI.3545-12.2012 · DOI · Paper page
- Maltsev, 2013, Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates, J. Am. Chem. Soc, 135, 2943, 10.1021/ja312415q · DOI
- Zarbiv, 2014, Lysine residues at the first and second KTKEGV repeats mediate α-synuclein binding to membrane phospholipids, Neurobiol. Dis, 70, 90, 10.1016/j.nbd.2014.05.031 · DOI
- Bussell, 2004, Effects of Parkinson's disease-linked mutations on the structure of lipid-associated α-synuclein, Biochemistry, 43, 4810, 10.1021/bi036135+ · DOI
- Fares, 2014, The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells, Hum. Mol. Genet, 23, 4491, 10.1093/hmg/ddu165 · DOI · Paper page
- Bartels, 2014, N-α-Acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation, PLoS One, 9, e103727, 10.1371/journal.pone.0103727 · DOI · Paper page
Cited by
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328
Role of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 308
Vecchio, L. M., Sullivan, P., Dunn, A. R., Bermejo, M. K., Fu, R., Masoud, S. T., Gregersen, E., Urs, N. M., Nazari, R., Jensen, P. H., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15432 · Cited by 56
Rivero-Ríos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y., & Hilfiker, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00556 · Cited by 31
Metadata
- Authors
- Follmer, C., Coelho-Cerqueira, E., Yatabe-Franco, D. Y., Araujo, G. D. T., Pinheiro, A. S., Domont, G. B., & Eliezer, D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 290
- Issue
- 46
- Pages
- 27660-27679
- ISSN
- 0021-9258
- Cited by
- 115
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1792 d)
- Funders
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- National Institutes of Health (R37AG019391)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). https://app.cochat.ai/papers/10.1074/jbc.m115.686584
- The paper
- Follmer, C., Coelho-Cerqueira, E., Yatabe-Franco, D. Y., Araujo, G. D. T., Pinheiro, A. S., Domont, G. B., & Eliezer, D. (2015). Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m115.686584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.